Advanced Life Sciences’ Once-Daily Cethromycin Non-Inferior To Biaxin In First Pivotal Trial
This article was originally published in The Pink Sheet Daily
Executive Summary
NDA for cethromycin to treat community-acquired pneumonia could be filed in second half of 2007, President John Flavin tells “The Pink Sheet” DAILY.
You may also be interested in...
Advanced LifeSciences Confirms Efficacy Of Cethromycin In Second Phase III Trial
Company now intends to focus on filing an NDA in community-acquired pneumonia and seeking a marketing partner for the product.
Advanced LifeSciences Confirms Efficacy Of Cethromycin In Second Phase III Trial
Company now intends to focus on filing an NDA in community-acquired pneumonia and seeking a marketing partner for the product.
Oscient’s Factive Clears FDA For Five-Day Community Acquired Pneumonia Indication
Antibiotic is the only fluoroquinolone approved in the U.S. for five-day treatment of both CAP and AECB.